Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use NEXLIZET® safely and effectively. See full prescribing information for NEXLIZET. NEXLIZET (bempedoic acid and ezetimibe) tablets, for oral use Initial U.S. Approval: 2020
Medication labelWhy this: Advisory · dailymed-prescription
NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Bempedoic acid, a component of NEXLIZET, is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin).
- generic_name
- bempedoic acid and ezetimibe
- product_names
- Bempedoic Acid and Ezetimibe
- ndc
- 72426-818, 72426-818-03, 72426-818-99, 72426-818-09
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en